A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY.
$4,798,925
| Recipient | REVAGENIX INC UEI D98QFZUPFXJ9 |
|---|---|
| Award ID | 75N93022C00061 |
| Award amount | $4,798,925 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Health and Human Services — National Institutes of Health |
| NAICS | 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) |
| PSC | AN12 |
| Start date | Sep 22, 2022 |
| End date | Mar 21, 2024 |
| Place of performance | SAN MATEO, CA |
| Record updated | Sep 27, 2022 |
View the official award record
More awards won by REVAGENIX INC
TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES.
Department of Health and Human Services · $12,376,688 · Jul 1, 2020
Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.
Search open bids